The Use of Adrenergic Receptor Selective Agents in Bladder and Lower Urinary Tract Syndromes
Duke University is seeking a company interested in commercializing a novel method to relieve irritable bladder symptoms. Benign prostatic hypertrophy (BPH), an age-related disease in which the prostate becomes enlarged, affects more than 50% of men over 60 years, and up to 90% of men over 80 years old. Current treatment for BPH includes the use of nonselective AR antagonists. Though this treatment is effective from a urinary standpoint, patients have experienced CNS and vascular side-effects. Similarly, while some selective antagonists have been shown to relieve urinary obstruction in BPH, they have not provided complete relief of bladder irritation symptoms. The technology under development is a selective AR which will potentially relieve such symptoms such as irritability in Lower Urinary Tract (LUTS) and in the bladder.